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RCI was classified in three categories 0 to 2 , 3 to 4 and 5 and 
higher. For this purpose we used Kaplan-Meier method and 
Cox proportional hazards modeling 
 
Results: Finally 550 patients with prostate cancer were 
included, with median age of 70 years old (47-85), Mean 
follow-up time was 136.8 months, between 5,6 and 245,8 
months. D’Amico risk classification distribution was for low 
risk, mediun and high 20.4%, 36,5% and 43,1% respectively. 
RCI distribution categories was as follows 61,5%, 21,8 and 
16,7%. Survival analysis showed significant differences 
(p<0.001) between RCI groups at 5 and 10 years. Survival 
probability was 98,2 and 88,5% ; 95% and 79,6% ; and 52,2% 
and 8,9% was respectively for each RCI category. 
 
Conclusion: RCI allowed for more accurate identification of 
men at highest risk for other cause mortality. 
Our results are in concordance with original RCI .This revised 
index may be used to aid medical decision making and 
personalized medecine for men with prostate cancer.  
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Purpose or Objective: The definition of the clinical target 
volume (CTV) for salvage radiotherapy after prostatectomy is 
based on clinical and pathologic variables of the tumor and 
consensus guidelines. Multiparametric-MRI is recommended 
to evaluate pelvic recurrences after radical prostatectomy 
when the PSA is low (0.2-2 ng/ml) but the benefit of planning 
individualised radiation treatment based on the results of MRI 
is unknown. We analysed whether all suspicious lesions 
detected with pelvic multiparametric MRI were included in 
the clinical target volume defined according to four current 
guidelines and we determined the percentage of missing 
target if this radiological information was lost. 
 
Material and Methods: We retrospectively reviewed the 
clinical records and multiparametric MRI studies of 70 
patients with PSA recurrence after radical prostatectomy. 
Salvage radiotherapy of at least the prostate bed was 
indicated in all cases. On the simulation CT scan of 33 
patients who had visible tumor recurrence in the MRI study, 
we delineated four different CTV according to RTOG, EORTC, 
PMH and FROGG consensus guidelines for postoperative 
prostate bed irradiation. We delineated a relapse CTV which 
included the radiological tumor recurrence plus 5 mm. For 
the PTV, we added a 5 mm margin. We compared volume size 
of the CTV and determined the percentage of geographically 
missed target (relapse PTV not included / relapse PTV).  
 
Results: Multiparametric-MRI was positive in 33/70 patients. 
Local recurrence occurred in 27 patients, mainly in the 
perianastomotic area (19). Mutiparametric-MRI detected 
positive lymph nodes in 7 patients, mostly in the external 
iliac region. The mean size of the lymph nodes was 10 mm 
(range 8-16 mm). The mean volumes of the CTV delineated 
according to the EORTC, RTOG, PMH and FROGG consensus 
were 81.5, 100.7, 109.3 and 99.7 cc, respectively. In 2 out of 
33 cases, the recurrence depicted in the pelvic MRI was not 
totally enclosed in the CTV, independently of the consensus 
guidelines used. The missed recurrences were located in the 
left retrovesical region (patient 1) and at the level of the 
penile bulb (patient 2) . The volumes of the relapsed PTV 
were 23.4 and 14.9 cc, respectively. The percentages of 
relapse PTV out of the PTV created according to each 
guideline were 41%, 59%, 44 and 44% in patient 1 and 44%, 
39%, 39% and 41% in patient 2. In 7 out of 70 patients (10%), 
lymph node recurrence would have been missed if we had 
only considered salvage prostate bed irradiation.  
 
Conclusion: Using current guidelines for CTV definition for 
salvage radiotherapy after prostatectomy, we found that the 
local recurrences depicted in the pelvic multiparametric MRI 
were totally covered in most patients. Multiparametric-MRI 
may help tailor local and lymph node CTV and identify lesions 
to treat with a higher dose 
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Purpose or Objective: To report the toxicity and preliminary 
biochemical outcomes with high-dose intensity-modulated 
radiation therapy (IMRT) to a dose of 82.8Gy in patients 
prostate cancer. 
 
Material and Methods: Between April 2002 and December 
2013, 757 patients with biopsy proven prostate cancer were 
treated with high-dose IMRT. While 398 patients received a 7 
or 8- field -IMRT -sliding window- technique up to a median 
total dose to the prostate of 77.4 Gy/1.8Gy, 359 patients 
were treated with a 2 arc-Volumetric Modulated ArcTherapy 
(VMAT) plans up to a median total dose to the prostate of 
82.0Gy/ 1.8Gy. In 264 high-risk prostate cancer patients the 
pelvic node region was treated to incorporate the nodes at 
risk. Total doses of 50.4Gy were prescribed to the pelvis. In 
29 % of SW patients and 23% of VMAT patients an additional 
boost of 5 to 16Gy was administered in cases of MRI-staged 
lymph node metastases. Acute and late toxicities were 
prospectively scored by the RTOG/ LENT SOMA morbidity 
grading scales (until 2009) and a modified CTCAEv3.0 score 
(since 2009), respectively. Biochemical failure was defined 
according to the Phoenix definition of nadir + 2ng/ml. The 
median follow- up time was 65 months (range,12-151 
months). 
 
Results: The IMRT dose distribution provided excellent PTV 
coverage and satisfying protection of all the organs at risk, 
with less than 2% of all patients experiencing grade (G) 3 
toxicities, G4 toxicities were not observed at all. In total 40.3 
/ 11 / 1.1% of patients developed acute G1/ 2/ 3 
genitourinary (GU) toxicities. 28%/ 3.1% of patients 
experienced acute G1/ 2 gastrointestinal (GI) side effects, no 
patient developed acute > G2 gastrointestinal symptoms. 
Late GU- and GI toxicity was mild with > 85% of the patients 
free from any GU/GI toxicity during follow-up and no time 
trend to increased rates or to higher grade of GU/GI- 
toxicity. Maximum late GU toxicities were G1/ 2/ 3 for 10/ 
2.5/ 1.6% of patients, respectively. Maximum late GI 
toxicities were G1/2 for 4.9 / 0.4%of patients. The 5-year 
freedom from biochemical failure (FFBF) was 87.8%for all 
patients and 95, 79.9 and 83.4% for low-, intermediate-, and 
high-risk disease. 
 
Conclusion: These data demonstrate that escalated -dose 
IMRT is a well tolerated technique in prostate cancer patients 
and the preliminary excellent biochemical control rates are 
encouraging.  
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Purpose or Objective: The fear of radiotherapy-induced 
urinary incontinence (URINC) often contraindicates post-
prostatectomy RT (POPRT), despite the lack of accurate data 
about its real incidence and severity. The purpose of this 
analysis was to analyze clinico-dosimetric factors predicting 
severe, self-reported URINC 1 and 2 years after POPRT. 
 
Material and Methods: In 2012 a longitudinal, observational 
study aimed at assessing URINC from POPRT including 
prophylactic whole-pelvis irradiation (WPRT) was activated at 
our Institute. For the evaluation of urinary toxicity, 2 
validated questionnaires, IPSS and ICIQ-SF, are to be filled-in 
by pts at baseline, at RT mid-point and end, at 3 and 6 
months after RT conclusion, and every 6 months thereafter. 
This analysis pertains to the first 101 pts correctly filling the 
questionnaires at baseline and at 12 months (60 also at 2 
years). Fifty-four and 47 pts were treated with adjuvant 
(ADV) and salvage (SALV) intent after a median of 4 and 38 
months, respectively, from radical prostatectomy (RP), with 
either conventional (n=42) or moderately hypofractionated 
(n=59) regimens, at a median 2-Gy equivalent dose (EQD2) to 
the prostatic bed of 70 and 74 Gy in ADV and SALV cohort, 
respectively, and a median EQD2 dose of WPRT of 50 Gy. 
 
Results: The mean baseline ICIQ scores were 7.8 and 4.8 in 
ADV and SALV cohorts, respectively (p=0.009). The 
corresponding values at 1 and 2 years were 7.4 vs 7.3 and 8.5 
vs 7.9, respectively. Severe URINC (³ 13 points) was recorded 
in 23% and 19% at 1 year, and in 37% and 21% of pts treated 
with ADV and SALV intent, respectively (p≤0.20). The 75th 
quartiles of ICIQ at 12 (ICIQ12) and 24 (ICIQ24) months (12 
and 13 points, respectively), were set as end-points for 
regression logistic analysis. Several clinico-dosimetric factors, 
including age, diabetes, hypertension, pT and pN stage, # of 
removed LNs, RT intent, time from RP to RT, fractionation, 
EQD2, adjuvant androgen deprivation (AAD), IQIQ and IPSS 
baseline values were analyzed. Variables with a p-value <0.20 
at univariable analysis were entered into a backward 
stepwise multivariable model indicating baseline ICIQ and 
nocturia (IPSS item #7) and AAD as predictors of ICIQ12 (AUC 
94%), while baseline ICIQ and EQD2 predicted ICIQ24 (AUC 
89%). 
 
 
 
Conclusion: The risk of long-term severe URINC 1 and 2 years 
after POPRT is strongly modulated by baseline URINC, and by 
AAD and higher EQD2, respectively (Figure 1).  
 
PO-0750  
Conventionally-fractionated VMAT vs. SBRT in prostate 
cancer:PSA kinetics, toxicity,quality of life 
M. Tambas
1Istanbul University Institute of Oncology, Radiation 
Oncology, Istanbul, Turkey 
1, F. Agaoglu1, A. Iribas1, M. Guveli1, Y. Dizdar1, M. 
Okutan2, D. Ozkan3, N. Tenekeci3, E. Darendeliler1 
2Istanbul University Institute of Oncology, Medical Physics, 
Istanbul, Turkey 
3Istanbul University Institute of Oncology, Radiology, 
Istanbul, Turkey 
 
Purpose or Objective: In the present study, conventionally 
fractionationed volumetric arc therapy (VMAT) and 
hypofractionated stereotactic body radiotherapy (SBRT) 
modalities were aimed to compare in terms of side effects 
and quality of life (QOL) in patients with localized prostate 
cancer.  
 
Material and Methods: Patients who admitted to I.U. 
Institute of Oncology with a diagnosis of localized prostate 
cancer during the period from March 2010 to December 2013 
were included into the study. Patients received radical RT 
with dose schedules of either 33.5 Gy/5 fr for SBRT or 75.6 
Gy/35 fr for VMAT. Acute and late side effects of treatment 
were evaluated according to CTCAE version 4. IPSS and 
EORTC QOL-PR25 forms were used to assess QOL at baseline, 
end of treatment and during follow-up. 
 
Results: Of the 48 patients (28 SBRT, 20 VMAT) who were 
included into the study, 40 (20 SBRT, 20 VMAT) were 
evaluated for their QOL status. All demographic and 
pathological features including median age of the patients, 
clinical manifestations, and the risk groups were found to be 
similar between treatment groups. PSA control rates were 
%100 in both arms during the follow up with a median of 23 
months. PSA nadir values were detected to be 0.5 ng/dl in 
both arms. PSA bounce was observed in 43% and 50% of 
patients in SBRT and VMAT arms, respectively. The 
magnitude of PSA bounce value was significantly higher in 
SBRT arm compared with VMAT (0.8 ng/dl vs. 0.1 ng/dl, 
p=0.01). PSA decline rate in VMAT arm was found to be 
significantly higher than in SBRT arm (p = 0.028). Grade 3 
rectal toxicity was not observed in any of the treatment 
arms. Although Grade 3 urinary side effects were not seen in 
patients treated with VMAT technique, 3 patients (10.7%) in 
SBRT arm with a history of TURP before RT experienced 
Grade 3 urinary toxicity. No significant difference was 
observed between the two arms concerning sexual activity 
functioning and sexual functioning scores whereas the scores 
at 10.5 and 13.5 months were found to be significantly 
decrased compared with baseline in both treatment arms. 
SBRT and VMAT arms did not differ significantly regarding 
urinary, incontinence, bowel symptom scores and IPSS 
obstruction scores. The magnitude of increase in IPSS scores 
at the end of the treatment compared with baseline were 
detected to be significantly higher in VMAT arm than SBRT 
arm (p=0.046). The decrease in hormonal symptom scores at 
4.5, 10.5 and 13.5 months compared with baseline was 
detected to be significantly higher in VMAT arm than SBRT 
arm (p=0.007, p=0.027, and p=0.021, respectively). 
 
